A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

NCT05129423 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Development of MTPS9579A was terminated for strategic/business reasons.

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: MTPS9579A
DRUG: Placebo

Sponsor

Genentech, Inc.